论文部分内容阅读
目的观察融合表达质粒 pcDNA3.1-SC 对 HBV 复制和表达的抑制效果。方法构建融合表达质粒 pcDNA3.1-SC,以100μg 肌肉接种 C_(57)BL/6 HBV DNA 转基因小鼠.2、4周后各加强免疫1次。然后动态检测小鼠血清抗-HBs、抗-HBc 的诱生,以及肝组织 HBsAg、HBcAg 和血清HBV DNA 的消长情况。结果接种后4、8、12周,小鼠血清抗-HBs 阳转率分别达到55%、67%和33%;而抗-HBc 阳转率低于20%;同时,与接种前相比,肝组织内 HBsAg、HBcAg 表达和血清 HBVDNA 水平呈逐渐减弱的趋势.在接种后8周,有1/3的小鼠已不能检出。结论融合表达质粒 pcD-NA3.1-SC 能够在一定程度上抑制转基因小鼠体内的 HBV DNA 复制和抗原表达,提示了研制乙型肝炎治疗性 DNA 疫苗的可能性。
Objective To observe the inhibitory effect of fusion expression plasmid pcDNA3.1-SC on HBV replication and expression. Methods The recombinant plasmid pcDNA3.1-SC was constructed and the C57BL / 6 HBV DNA transgenic mice were inoculated intramuscularly with 100|Ìg muscle, and the mice were boosted once and 4 weeks later. Then the anti-HBs, the induction of anti-HBc, and the growth and disappearance of HBsAg, HBcAg and serum HBV DNA in liver tissue were detected dynamically. Results At 4, 8 and 12 weeks after inoculation, the positive rates of anti-HBs in mice were 55%, 67% and 33%, respectively, while the positive rates of anti-HBc were less than 20%. At the same time, HBsAg, HBcAg expression and serum HBVDNA level in the liver tissue showed a gradual decline.Of the 8 weeks after inoculation, one third of the mice have been unable to detect. Conclusion The fusion expression plasmid pcD-NA3.1-SC can inhibit HBV DNA replication and antigen expression in transgenic mice to a certain extent, suggesting the possibility of developing a therapeutic DNA vaccine for hepatitis B.